Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d

Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,

make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising

from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Incorporated in the Cayman

Islands with limited liability)

CHANGE OF PRINCIPAL PLACE OF BUSINESS

The board (the "Board")

of directors (the "Directors") of Ascentage Pharma Group International (the "Company") announces

that the principal place of business of the Company in Hong Kong has been changed to Unit 906, 9/F., Haleson Building, 1 Jubilee Street,

Central, Hong Kong with effect from April 1, 2026.

Suzhou, People's Republic of China, April 1, 2026

As at the date of this announcement,

the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote1

as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei and Dr. David SidranskyNote2

and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.